Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 2, 2002 - Issue 3
Submit an article Journal homepage
170
Views
12
CrossRef citations to date
0
Altmetric
Review

Molecular diagnosis of HIV

John R Clarke Department of Genitourinary Medicine, Division of Medicine, Imperial College of Science, Technology and Medicine, St Mary’s Campus, Paddington, London W2 1PG, UK. [email protected]
Pages 233-239 | Published online: 09 Jan 2014

References

  • Riddler SA, Mellors JW HIV-1 viral load and clinical outcome: review of recent studies. AIDS 11(Suppl. A), S141—S148 (1997).
  • •A review of the clinical usefulness of viral load assessments.
  • Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus Type 1 infection. Nature 373,117–122. (1995).
  • •Describe the dynamics of HIV-1 replication and clearance of the virus following initiation of treatment.
  • Ho DD, Neumann AU, Perelson AS et al Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123–126 (1995).
  • •See [2].
  • Perelson AS, Essunger P, Cao Yet al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 387, 188–191 (1997).
  • •Mathematical calculations of decay of viral load following combination antiretroviral therapy. The paper under-estimated the length of time required to eliminate the virus from the host.
  • Panteleo G, Graziosi C, Demarest JF et al HIV infection is active and progressive in lymphoid tissue during the clinical latent stage of disease. Nature 362,355–358 (1993).
  • •Shows that most HIV replication is occurring in the lymph nodes during the clinical asymptomatic phase of the disease.
  • Embretson J, Zupancic M, Ribas JL et al. Massive covert infection of helper T-lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362, 359–362 (1993).
  • •See [5].
  • Haase AT, Henry K, Zupancic M et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274, 985–989. (1996)
  • •Shows the replication of HIV in lymph nodes and the destruction of the germinal centers.
  • Mellors JW, Rinaldo CR, Gupta P et al Prognosis of HIV-1 infection predicted by quantity of virus in plasma. Science 272, 1167–1170 (1996).
  • •A very important paper that shows that HIV-1 viral load in plasma is linked to disease progression and shows the importance of viral load as a surrogate marker for HIV-1 disease progression.
  • Ho DD. Time to hit HIV early and hard. N Engl J. Med. 333,450–451 (1995).
  • •Editorial arguing for early treatment of HIV infected patients with antiretroviral drugs. The concept is that the longer HIV is undetectable in plasma the better the long term outcome for the patient. mDewar RE, Highbarger HC, Sarmiento MD et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus Type 1 burden in human plasma.' Infect. Dis. 170, 1172–1179 (1994).
  • Wilbur J, Urdea MS. Quantification of viral nucleic acids using branched DNA signal amplification. In: Molecular Methods Jr Virus Detection. Wieldbrauk DL, Farkas DH (Eds.), Academic Press, London, UK 131–145 (1995).
  • Schuurman R, Descampes D, Weverling GJ et al Multicenter comparison of the three commercial methods for quantification of human immunodeficiency virus Type 1 RNA in plasma. J. Chn. Microbial 34, 3016–3022 (1996).
  • Todd J, Pachl C, White R et at Performance characteristics for quantification of plasma HIV-1 RNA using brached DNA signal amplification technology J. Acquir. Immun. Def: Syndr. 10\(Supp1.2), S35—S44 (1995).
  • Holodniy M, Mole L, Winters M, Merigan TC. Diurnal and short-term stability of HIV virus load as measured by gene amplification.' Acquir. Immun. Def Syndr. 7, 363–368 (1994).
  • Holodniy M, Mole L, Yen-Lieberman B et al. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in Vacutainer CPT, Vacutainer PPT, and standard Vacutainer tubes. Clin. Microbial 33, 1562–1566 (1995).
  • Yen-Lieberman D, Brambilla D, Jackson B et aZ Evaluation of a quality assurance program for quantitation of human immunodeficiency virus Type 1 RNA in plasma by the AIDS clinical trials group virology laboratories.' Chn. Microbial 34, 2695–2701 (1996).
  • Van Damme AM, Schmit J-C, Van Dooren S et al. Quantification of HIV-1 RNA in plasma: comparable results with NASBA HIV-1 RNA QT and the Amplicor monitor test. J. Acquir. Immun. Def: Syndr. 13, 127–139 (1996).
  • Delamere C, Burgard M, Deveau C et al. Longitudinal study of HIV-1 RNA concentrations during the asymptomatic stage of HIV-1 infection measured using Amplicor HIV monitor and NASBA HIV-1 RNA QT. J. Med. Viral. 54, 60–68 (1998).
  • Mulder J, McKinney N, Christopherson C et al. Rapid and simple PCR assay for uantitation of human immunodeficiency virus Type 1 RNA in plasma: application to acute retroviral infection.' Clin. Microbial 32, 294–300 (1994).
  • Deeks SG, Coleman RL, White R et al. Variance of plasma human immunodeficiency virus type-1 RNA levels measured by branched DNA within and between days." Inf Dis. 176, 514–517 (1997).
  • Revets H, Marissens D, De Wit S et al. Comparative evaluation of NASBA HIV-1 RNA QT, Amplicor HIV Monitor and Quantiplex HIV RNA assay: three methods for quantification of human immunodeficiency virus Type 1 RNA in plasma.' Chn. Microbial 34, 1058–1064 (1996).
  • Swanson P, Soriano V, Devare SG, Hackett J. Comparative performance of three viral load assays on human immunodeficiency virus Type 1 isolates representing group M (subtypes A to G) and group 0: LCx HIV RNA quantitative, Amplicor HIV-1 monitor version 1.5 and Quantiplex HIV-1 RNA version 3.0. J. Chn. Microbial 39, 862–870 (2001).
  • Clarke JR, Galpin S, Braganza R et al. Comparative quantification of diverse serotypes of HIV1 in plasma from a diverse population of patients. J. Med. Viral 62, 445–449 (2000).
  • O'Shea S, Christie I, Cranston R et al. Problems in the interpretation of HIV-1 viral load assays using commercial reagents.' Med. Viral 61, 187–194 (2000).
  • Clarke JR, McClure M, HIV viral load testing.' Infect. 38,141–146 (1999).
  • Lewin SR, Vesanen M, Kostrikis Let al. Use of real time PCR and molecular beacons to detect virus replication in human immunodeficiency virus Type 1 infected individuals on prolonged effective antiretroviral therapy.' Viral 73, 6099–6103 (1999).
  • Drosten C, Seifried E, Roth WK. Taqman 5' nuclease human immunodeficiency virus Type 1 PCR assay with phage packaged competitive internal control for high-throughput blood donor screening. fain. Microbial 39, 4302–4308 (2001).
  • Wittwer CF, Fillmore GC, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. BiaTechniques 22, 130–138 (1997).
  • Wntwer CT, Ririe KM, Andrew RV et al. The lightcycler: a microvolume multisample fluorimeter with rapid temperature control. BiaTechniques 22, 176–181 (1997).
  • Eisenstein B. A new method of using molecular genetics for medical diagnosis. N Engl. J. Med. 322, 178–183 (1990).
  • Larder BA, Kellam R Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV infected lymphocytes. AIDS 5, 137–144 (1991).
  • •The first PCR based molecular test that could be applied to the detection of HIV drug resistant genotypes.
  • Kaye S, Loveday C, Tedder P.S. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus Type 1 infected patients treated with zidovudine.j Med. Viral 37, 241–246 (1992).
  • •The first point mutation assay for the detection of resistance mutations in HIV
  • Stuyver L, Wyseur A, Rombout A et al. Line probe assay for rapid detection of drug selected mutations in the human immunodeficiency virus Type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41, 284–291.
  • •The first commercially available assay for the detection of resistance mutations in llv
  • Clarke JR, Kaye S, Babiker A et al. Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues.' Viral. Meth. 88, 117–124 (2000).
  • •Surressful use of line probe technology in clinical trials.
  • Clarke JR, Braganza R, Mirza A et al. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy.' Med. Viral. 59, 364–368. (1999).
  • •Use of the line probe assay in routine diagnosis of HIV resistance in pregnant women.
  • Puchhammer-Stockl E, Schmied B, Mandl CW et al. Comparison of line probe assay (LiPA) and sequence analysis for detection of HIV-1 drug resistance. J. Med. Viral. 57, 283–289 (1999).
  • Hirsch MS, Conway B, D'Aquila RT et al. Antiretroviral drug resistance testing in adults with HIV infection; implications for clinical management. J. Am. Med. Assoc. 279, 1984–1991 (1998).
  • •Review of all the clinically relevant mutations associated with HIV-1 drug resistance.
  • Elbeik T, Hoo B, Campodonico M et al. Detection of newly emerging primary genotypic mutations at less than 50 copies/ml with maintained presence at breakthrough in longitudinal plasma samples from patients on triple combination therapy. Antiviral Ther. 6, S49 (2001).
  • •Describe the versatility of sequence based assays for sequencing difficult samples.
  • Beddows S, Galpin S, Johargy A et a/. HIV-1 genetic subtypes and antiretroviral therapy resistance testing. AIDS14, S118 (2000).
  • •Describe the versatility of sequence based assays for sequencing difficult samples.
  • Erali M, Page S, Reimer LG, Hillyard DR Human immunodeficiency virus Type 1 drug resistance testing: a comparison of three sequence based methods. Jain. Microbial 39, 2157–2165 (2001).
  • •Describe the versatility of sequence based assays for sequencing difficult samples.
  • Mracna M, Becker-Pergola G, Dileans J et al. Performance of Applied Biosystems Viroseq HIV-1 genotyping system for sequence based analysis of non-subtype B human immunodeficiency virus Type 1 from Uganda. Jain. Microbial 39, 4323–4327 (2001).
  • •Describe the versatility of sequence based assays for sequencing difficult samples.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.